MIN-101
MIN-101 (former developmental code names CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. As of August 2015, the drug is in phase II clinical trials.
MIN-101
MIN-101 (former developmental code names CYR-101, MT-210) is a 5-HT2A and σ2 receptor antagonist that is under development by Minerva Neurosciences for the treatment of schizophrenia. One of its metabolites also has some affinity for the H1 receptor. As of August 2015, the drug is in phase II clinical trials.
has abstract
MIN-101 (former developmental ...... s in phase II clinical trials.
@en
CAS number
359625-79-9
IUPAC name
2-1-[2-(4-Fluorophenyl)-2-oxoethyl]piperidin-4-yl]methyl]-3H-isoindol-1-one
@en
PubChem
thumbnail
Wikipage page ID
48,830,910
Wikipage revision ID
713,776,942
ChemSpiderID
legal status
Investigational
molecular weight
3.66428623e+2
routes of administration
StdInChIKey
RNRYULFRLCBRQS-UHFFFAOYSA-N
hypernym
comment
MIN-101 (former developmental ...... s in phase II clinical trials.
@en
label
MIN-101
@en
